

Ortho Regenerative Technologies Announces Private Placement

Kirkland, QC, October 27, 2017 – Ortho Regenerative Technologies Inc. (CSE: **ORTH.CN**) (“**Ortho RTi**” or the “**Corporation**”) is pleased to announce a non-brokered private placement of up to 3,000,000 units (“**Units**”) at a price of \$0.50 per Unit for gross proceeds of \$1,500,000.

Each Unit will consist of one Class “A” common share of the Corporation (the “**Share**”) and one-half (½) of one non-transferable Share purchase warrant (each whole Share purchase warrant, a “**Warrant**”) of the Corporation. Each whole Warrant shall entitle the holder thereof to acquire one Share of the Corporation at an exercise price of \$0.70 per Share at any time on or before the close of business on a date that is eighteen (18) months from the Closing Date (as hereinafter defined). If, during the eighteen (18) months after the Closing Date, the Corporation's weighted average Share price for 30 consecutive trading days equals or exceeds \$1.00, the Corporation may give notice to the Warrant holders that they must exercise their remaining Warrants within a period of 30-days from the date of receipt of the notice.

The net proceeds from the Offering will be used to fund research and development costs and for general corporate purposes.

This press release does not constitute an offer to sell or a solicitation of an offer to buy securities in the United States. The securities referenced herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws and may not be offered or sold in the United States except in compliance with one or more exemptions from the registration requirements of the U.S. Securities Act and applicable securities laws.

About Ortho Regenerative Technologies Inc.

Ortho RTi is an emerging Orthopaedic and Sports Medicine technology company dedicated to the development of novel therapeutic tissue repair technology to dramatically improve the success rate of sports medicine surgeries for soft tissue injuries. Our proprietary biopolymer has been specifically designed to increase the healing rates of injuries to tendons, meniscus and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Visit us on the internet at www.orthorti.com.

Forward-Looking Statements

This news release may contain certain forward-looking statements regarding the Corporation's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES

assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Corporation disclaims any intention or obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.

For further Information, please contact:

Stephen Kilmer
Investor & Media Relations
647.872.4849
kilmer@orthorti.com